clinical trial · NCT04561518
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Transthyretin-Mediated AmyloidosisATTR Amyloidosis
brief summary
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
started
Nov 23, 2020
primary completion
Sep 1, 2030
completion
Sep 1, 2030
last updated
Mar 31, 2026
official title
ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol